Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies. Materials and Methods We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay. Results Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments. Conclusion The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.
Abstract
Purpose Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies. Materials and Methods We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay. Results Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments. Conclusion The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.
참고문헌 (18)
- Rubin LG, "2013 IDSA clinical practice guideline for vaccination of the immunocompromised host", Clin Infect Dis, 58, pp.e44~e100 (2014)
- Shildt RA, "Antibody response to pneumococcal vaccine in patients with solid tumors and lymphomas", Med Pediatr Oncol, 11, pp.305~309 (1983)
- Nordoy T, "Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae", Med Oncol, 19, pp.71~78 (2002)
- Hung TY, "Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients", Cancer, 123, pp.4215~4223 (2017)
- Wumkes ML, "Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours", Vaccine, 31, pp.6177~6184 (2013)
- Rodgers GL, "Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule", Vaccine, 31, pp.4765~4774 (2013)
- Moore MR, "Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA : a matched case-control study", Lancet Respir Med, 4, pp.399~406 (2016)
- 송준영, "Clinical Implications of Pneumococcal Serotypes: Invasive Disease Potential, Clinical Presentations, and Antibiotic Resistance", Journal of Korean Medical Science, 28(1), pp.4~15 (2013), 대한의학회
- Song JY, "Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults", Vaccine, 33, pp.4647~4652 (2015)
- Burton RL, "Development and validation of a fourfold multiplexed opsonization assay(MOPA4)for pneumococcal antibodies", Clin Vaccine Immunol, 13, pp.1004~1009 (2006)
- Beyer WE, "Seroprotection rate, mean fold increase, seroconversion rate:which parameter adequately expresses seroresponse to influenza vaccination?", Virus Res, 103, pp.125~132 (2004)
- Song JY, "Pneumococcal vaccine and opsonic pneumococcal antibody", J Infect Chemother, 19, pp.412~425 (2013)
- Romero-Steiner S, "Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity", Clin Infect Dis, 29, pp.281~288 (1999)
- Kumar D, "Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients", J Infect Dis, 187, pp.1639~1645 (2003)
- Durando P, "Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults", Clin Microbiol Infect., 19(Suppl 1), pp.1~9 (2013)
- Addiego JE Jr, "Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease : Children's Cancer Study Group Report", Lancet, 2, pp.450~452 (1980)
- Frederiksen B, "Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease", Eur J Haematol, 43, pp.45~49 (1989)
- Sinisalo M, "Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia", Vaccine, 26, pp.82~87 (2007)